MAGNI, FULVIO
 Distribuzione geografica
Continente #
NA - Nord America 37.161
AS - Asia 19.448
EU - Europa 17.236
SA - Sud America 2.632
Continente sconosciuto - Info sul continente non disponibili 1.409
AF - Africa 392
OC - Oceania 45
Totale 78.323
Nazione #
US - Stati Uniti d'America 35.344
SG - Singapore 6.216
IT - Italia 5.020
CN - Cina 4.171
VN - Vietnam 3.858
DE - Germania 2.308
HK - Hong Kong 2.267
RU - Federazione Russa 1.962
BR - Brasile 1.940
SE - Svezia 1.841
IE - Irlanda 1.578
CA - Canada 1.492
GB - Regno Unito 928
UA - Ucraina 905
FR - Francia 689
IN - India 556
BD - Bangladesh 438
FI - Finlandia 419
AT - Austria 403
KR - Corea 354
NL - Olanda 240
AR - Argentina 235
TR - Turchia 229
ID - Indonesia 202
ES - Italia 192
IQ - Iraq 184
PL - Polonia 170
JP - Giappone 162
MX - Messico 142
ZA - Sudafrica 141
DK - Danimarca 132
PK - Pakistan 122
SA - Arabia Saudita 108
EC - Ecuador 102
BE - Belgio 98
VE - Venezuela 91
CO - Colombia 88
PH - Filippine 88
CH - Svizzera 69
UZ - Uzbekistan 58
MA - Marocco 57
CL - Cile 51
MY - Malesia 47
PY - Paraguay 46
JM - Giamaica 45
LT - Lituania 45
IR - Iran 38
AU - Australia 37
CZ - Repubblica Ceca 33
EG - Egitto 31
RO - Romania 31
KE - Kenya 30
AE - Emirati Arabi Uniti 29
JO - Giordania 29
PE - Perù 29
TN - Tunisia 29
AZ - Azerbaigian 28
IL - Israele 28
KZ - Kazakistan 28
NP - Nepal 27
TH - Thailandia 27
UY - Uruguay 27
BG - Bulgaria 26
CR - Costa Rica 23
ET - Etiopia 23
GR - Grecia 22
EU - Europa 20
LB - Libano 20
TW - Taiwan 20
BO - Bolivia 19
HN - Honduras 19
PT - Portogallo 19
DZ - Algeria 18
OM - Oman 18
NI - Nicaragua 16
DO - Repubblica Dominicana 15
KG - Kirghizistan 14
NO - Norvegia 14
PA - Panama 14
TT - Trinidad e Tobago 14
PS - Palestinian Territory 13
SY - Repubblica araba siriana 11
AL - Albania 10
BY - Bielorussia 10
LV - Lettonia 10
GT - Guatemala 9
HU - Ungheria 9
MT - Malta 9
RS - Serbia 9
CI - Costa d'Avorio 8
QA - Qatar 8
BB - Barbados 7
BH - Bahrain 7
KW - Kuwait 7
SK - Slovacchia (Repubblica Slovacca) 7
SN - Senegal 7
SV - El Salvador 7
LA - Repubblica Popolare Democratica del Laos 6
LU - Lussemburgo 6
MU - Mauritius 6
Totale 76.814
Città #
Ann Arbor 4.349
Ashburn 3.677
Singapore 3.533
San Jose 2.698
Hong Kong 2.204
Milan 1.857
Woodbridge 1.853
Fairfield 1.649
Dublin 1.531
Chandler 1.521
Houston 1.289
Frankfurt am Main 1.203
Ho Chi Minh City 1.159
Wilmington 1.024
New York 898
Hanoi 894
Jacksonville 888
Toronto 880
Dallas 802
Santa Clara 788
Dearborn 747
Seattle 716
Council Bluffs 676
Los Angeles 674
Beijing 573
Cambridge 552
Chicago 508
Hefei 503
Princeton 465
The Dalles 408
Vienna 343
Shanghai 334
Seoul 327
Nanjing 302
Rome 269
Lauterbourg 255
Buffalo 247
São Paulo 238
Moscow 208
Munich 207
Helsinki 189
Boardman 186
Altamura 182
Lawrence 175
Columbus 160
Phoenix 152
Lachine 145
Montréal 142
Orem 142
Da Nang 137
Dong Ket 127
London 120
Nanchang 119
Guangzhou 115
Warsaw 112
Brooklyn 109
Jakarta 108
Atlanta 105
Haiphong 105
Tokyo 103
Fremont 100
Montreal 97
Denver 94
Kent 94
Brussels 85
San Diego 84
Biên Hòa 82
Turin 82
Hải Dương 81
Baghdad 79
Chennai 78
Ottawa 78
Andover 77
Nuremberg 77
Shenyang 77
Changsha 75
Washington 72
Ha Long 69
Hebei 66
Johannesburg 65
Rio de Janeiro 63
Salt Lake City 63
Tianjin 63
Amsterdam 62
Quận Bình Thạnh 61
Stockholm 60
Figino 59
Boston 58
Manchester 58
Zhengzhou 58
Naples 55
Poplar 55
Ninh Bình 54
North Kansas City 54
Florence 53
Tashkent 53
San Francisco 52
Lissone 50
Jinan 49
Philadelphia 49
Totale 48.723
Nome #
Molecular signatures of medullary thyroid carcinoma by matrix-assisted laser desorption/ionisation mass spectrometry imaging 624
Viewing coffee fine roots under a molecular lens: Mapping the distribution of relevant metabolites by MALDI-MS imaging 616
Evolution of Nanoparticle Protein Corona across the Blood-Brain Barrier 609
Proteomics of liquid biopsies: Depicting RCC infiltration into the renal vein by MS analysis of urine and plasma 582
In-Depth mapping of the urinary N-glycoproteome: Distinct signatures of ccRCC-related progression 559
Comparative membrane proteomics: A technical advancement in the search of renal cell carcinoma biomarkers 535
3D bioprinted colorectal cancer models based on hyaluronic acid and signalling glycans 520
Effects of Hematuria on the Proteomic Profile of Urinary Extracellular Vesicles: Technical Challenges 502
Differential protein profiling of renal cell carcinoma urinary exosomes 497
Respiratory metabolism and calorie restriction relieve persistent endoplasmic reticulum stress induced by calcium shortage in yeast 494
Cytological Cytospin Preparation for the Spatial Proteomics Analysis of Thyroid Nodules Using MALDI-MSI 490
MALDI mass spectrometry imaging shows a gradual change in the proteome landscape during mouse ovarian folliculogenesis 482
11C-Labelling of N-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl]arylcarboxamide Derivatives and Evaluation as Potential Radioligands for PET imaging of Dopamine D3 Receptors 481
Urinary exosomes and diabetic nephropathy: a proteomic approach 478
Antigen Retrieval and Its Effect on the MALDI-MSI of Lipids in Formalin-Fixed Paraffin-Embedded Tissue 478
Cholinergic ligand [C-11]MP4A: Improved 4-acetoxypiperidine precursor synthesis via LC-APCI/MS characterisation and improved radioligand HPLC purification 470
Histology-guided proteomic analysis to investigate the molecular profiles of clear cell Renal Cell Carcinoma grades 470
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine 463
The putative role of MALDI-MSI in the study of Membranous Nephropathy 456
Rendering the invisible visible: adding a molecular dimension to pathology with spatial omics 450
ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine 447
Feasibility Study for the MALDI-MSI Analysis of Thyroid Fine Needle Aspiration Biopsies: Evaluating the Morphological and Proteomic Stability Over Time 443
Biallelic PI4KA Mutations Disrupt B-Cell Metabolism and Cause B-Cell Lymphopenia and Hypogammaglobulinemia 439
Serum biomarkers of Renal Cell Carcinoma assessed using a protein profiling approach based on ClinProt technique 434
MALDI-MSI Pilot Study Highlights Glomerular Deposits of Macrophage Migration Inhibitory Factor (MIF) as a Possible Indicator of Response to Therapy in Membranous Nephropathy 424
11C-radiosynthesis and preliminary human evaluation of the disposition of the ACE inhibitor [11C]Zofenoprilat 423
The proteomic landscape of renal tumors 423
MALDI-MSI Approach to Renal Biopsies of Patients with Fabry Disease 415
MALDI imaging in Fabry nephropathy: a multicenter study 414
Urinary proteomics for the study of genetic kidney diseases 411
Picture this: Mass Spectrometry Imaging to unveil the multiomic layers of the tumor immune environment 403
A MALDI-Mass Spectrometry Imaging method applicable to different formalin-fixed paraffin-embedded human tissues 401
Mutual Information Optimization for Mass Spectra Data Alignment 399
Analysis of Hashimoto's thyroiditis on fine needle aspiration samples by MALDI-Imaging 398
Ex vivo thyroid fine needle aspirations as an alternative for MALDI-MSI proteomic investigation: intra-patient comparison 394
Proteomics for the diagnosis of thyroid lesions: Preliminary report 389
Primary cell cultures from human renal cortex and renal-cell carcinoma evidence a differential expression of two spliced isoforms of Annexin A3 389
TdT expression in germ cell tumours: a possible immunohistochemical cross-reaction and diagnostic pitfall 389
Detecting Proteomic Indicators to Distinguish Diabetic Nephropathy from Hypertensive Nephrosclerosis by Integrating Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging with High-Mass Accuracy Mass Spectrometry 389
Feasibility of MALDI-MSI-Based Proteomics Using Bouin-Fixed Pathology Samples: Untapping the Goldmine of Nephropathology Archives 388
Improved synthesis and radiolabeling of [C-11]MP4A, a suitable ligand for the investigation of the cholinergic system using PET 387
Urinary extracellular vesicles and salt-losing tubulopathies: A proteomic approach 387
Proteomics imaging and the kidney 383
High Spatial Resolution MALDI-MS Imaging in the Study of Membranous Nephropathy 383
The management of haemoglobin interference for the MALDI-MSI proteomics analysis of thyroid fine needle aspiration biopsies 381
Different expression of Fibrinopeptide A and related fragments in serum of type 1 diabetic patients with nephropathy 377
Erratum: Spatial Multiomics of Lipids, N-Glycans, and Tryptic Peptides on a Single FFPE Tissue Section (Journal of Proteome Research (2022) 21: 11 (2798−2809) DOI: 10.1021/acs.jproteome.2c00601) 375
Matrix-assisted laser desorption/ionisation mass spectrometry imaging in the study of gastric cancer: A mini review 375
Increased susceptibility to plasma lipid peroxidation in Alzheimer disease patients 373
MALDI-MSI as a Complementary Diagnostic Tool in Cytopathology: A Pilot Study for the Characterization of Thyroid Nodules 371
Spatial resolution of renal amyloid deposits through MALDI-MSI: a combined digital and molecular approach to monoclonal gammopathies 370
Proteomic profiles of thyroid tumors by Mass Spectrometry-Imaging on Tissue Microarrays 369
Functional heterogeneity of lymphocytic patterns in primary melanoma dissected through single-cell multiplexing 369
Primary cell cultures arising from normal kidney and renal cell carcinoma retain the proteomic profile of corresponding tissues 368
Protein profiling of microdomains purified from renal cell carcinoma and normal kidney tissue samples 365
Alterations of the serum peptidome in renal cell carcinoma discriminating benign and malignant kidney tumors 363
Robust conclusions in mass spectrometry analysis 363
Proteomics for the study of new biomarkers in Fabry disease: State of the art 361
Novel domain-selective ACE-inhibiting activity of synthetic growth hormone secretagogues 356
Proteome analysis in thyroid pathology 356
Human urine biomarkers of renal cell carcinoma evaluated by ClinProt 354
Molecular trait of follicular-patterned thyroid neoplasms defined by MALDI-imaging 353
The PAF-acether receptor antagonist BN-52021 inhibits mediator release during guinea-pig active lung anaphylaxis 352
Advances in membranous vesicle and exosome proteomics improving biological understanding and biomarker discovery 350
Characterization of prion protein-enriched domains, isolated from rat cerebellar granule cells in culture 349
Tumor size, stage and grade alterations of urinary peptidome in RCC 349
Expression of heat shock protein 27 in human renal cell carcinoma 347
Poster: Characterization of distinguishing regions for renal cell carcinoma discrimination 347
Histoproteomic characterization of localized cutaneous amyloidosis in X-linked reticulate pigmentary disorder 347
The urinary proteome and peptidome of renal cell carcinoma patients: A comparison of different techniques 342
Synthesis and in vivo evaluation of 3-[C-11]methyl-(3-methoxy-naphthalen)-2-yl-(1-benzyl-piperidin)-4-yl-acetate (SB-235753), as a putative dopamine D-4 receptors antagonist for PET 341
Cytomolecular Classification of Thyroid Nodules Using Fine-Needle Washes Aspiration Biopsies 340
Characterization of heat shock protein 27 phosphorylation sites in renal cell carcinoma 338
The journey towards clinical adoption of MALDI-MS-based imaging proteomics: from current challenges to future expectations 337
Proteomic knowledge of human aquaporins 336
Unsupervised neural networks as a support tool for pathology diagnosis in MALDI-MSI experiments: A case study on thyroid biopsies 335
A hyphenated microLC-Q-TOF-MS platform for exosomal lipidomics investigations: Application to RCC urinary exosomes 331
Lipidomic typing of colorectal cancer tissue containing tumour-infiltrating lymphocytes by MALDI mass spectrometry imaging 329
Aberrant N-glycosylation patterns related to serum IgG subclasses in Idiopathic membranous nephropathy 328
Urinary Signatures of Renal Cell Carcinoma Investigated by Peptidomic Approaches 327
Definition of IgG Subclass-Specific Glycopatterns in Idiopathic Membranous Nephropathy: Aberrant IgG Glycoforms in Blood 326
Analysis of correlation structures in renal cell carcinoma patient data 326
[11C]RN5: A new agent for the in vivo imaging of myocardial α1-adrenoceptors 325
Proteomic analysis in clear cell renal cell carcinoma: identification of differentially expressed protein by 2-D DIGE 325
Differential expression of AQP1 in microdomain-enriched membranes of Renal Cell Carcinoma 318
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma 317
Urinary Peptidome and Proteome Alterations Related to Tumor Progression and Invasion in RCC 313
Palmitic is the main fatty acid carried by lipids of detergent-resistant membrane fractions from neural and non-neural cells 312
A Mutual Information Approach to Data Integration for Alzheimer’s Disease Patients 310
A molecular imaging approach to individuate tumour infiltrating lymphocytes 309
Customization of LC-MS-based proteomic workflows for biological studies in the clinical field 308
Proteomics in thyroid cytopathology: Relevance of MALDI-imaging in distinguishing malignant from benign lesions 307
An Alternative Approach in Endocrine Pathology Research: MALDI-IMS in Papillary Thyroid Carcinoma 303
Downregulation of C3 and C4A/B complement factor fragments in plasma from patients with squamous cell carcinoma of the penis 301
Intraluminal proteome and peptidome of human urinary extracellular vesicles 301
Untargeted Mass Spectrometry Approach to Study SARS-CoV-2 Proteins in Human Plasma and Saliva Proteome 299
Towards the standardization of mitochondrial proteomics: the Italian mt-HPP initiative 298
Modulation of urinary peptidome in humans exposed to high altitude hypoxia 298
Mapping the distribution of bioactive compounds and aroma/flavour precursors in green coffee beans with an integrated mass spectrometry-based approach 297
α-1-Antitrypsin detected by MALDI imaging in the study of glomerulonephritis: Its relevance in chronic kidney disease progression 296
Totale 38.921
Categoria #
all - tutte 242.069
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 242.069


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.411 0 0 0 415 200 267 119 192 157 244 282 535
2022/20236.038 672 1.860 486 603 352 861 72 375 381 62 183 131
2023/20244.729 138 156 192 320 517 1.360 990 125 295 76 121 439
2024/202510.317 472 928 598 459 902 393 568 461 1.112 1.657 1.043 1.724
2025/202629.636 4.153 2.229 2.292 3.037 3.134 1.418 4.045 1.218 2.136 2.260 1.714 2.000
2026/20275.143 913 1.166 2.918 146 0 0 0 0 0 0 0 0
Totale 78.323